Dr. David Nierengarten


Image: Dr. David Nierengarten

David Nierengarten is an analyst covering stocks in the biotechnology sector. His prior sellside research experience at Robert W. Baird & Co. covered biotechnology companies of all market capitalizations, with a focus on oncology and rare diseases. Nierengarten's prior early-stage venture capital investing experience helps him evaluate developmental-stage biotechnology companies that comprise his current major coverage focus. His experience on the other side of that equation, in a clinical-stage, venture-backed biotechnology company, provides him with additional insights into corporate operations. He received his bachelor's degree in biochemistry from the University of Wisconsin-Madison and his Ph.D. in molecular and cell biology from the University of California Berkeley.

Recent Quotes

"SNSS does have a path forward in Europe, where it has a shot at approval for Qinprezo."

The Life Sciences Report Interview with David Nierengarten (8/26/15)
more >

"We are expecting approval in the European Union of SNSS' vosaroxin."

— Dr. David Nierengarten, Wedbush (7/30/15)
more >

"SNSS says filing the MAA in the EU is now its top priority."

— Dr. David Nierengarten, Wedbush (7/23/15)
more >

"Data show that SNSS' vosaroxin has a potential treatment role in AML."

— Dr. David Nierengarten, Wedbush (6/12/15)
more >

"SNSS ended Q1/15 with $40M in cash and cash equivalents."

— Dr. David Nierengarten, Wedbush (5/5/15)
more >

"SNSS will present further analyses of the vosaroxin data in June."

— Dr. David Nierengarten, Wedbush (3/16/15)
more >

Due to permission requirements, not all quotes are shown.